JP2018504112A5 - - Google Patents

Download PDF

Info

Publication number
JP2018504112A5
JP2018504112A5 JP2017536271A JP2017536271A JP2018504112A5 JP 2018504112 A5 JP2018504112 A5 JP 2018504112A5 JP 2017536271 A JP2017536271 A JP 2017536271A JP 2017536271 A JP2017536271 A JP 2017536271A JP 2018504112 A5 JP2018504112 A5 JP 2018504112A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
cxcr4
sequence
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017536271A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018504112A (ja
JP6863897B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2016/050005 external-priority patent/WO2016109872A1/en
Publication of JP2018504112A publication Critical patent/JP2018504112A/ja
Publication of JP2018504112A5 publication Critical patent/JP2018504112A5/ja
Application granted granted Critical
Publication of JP6863897B2 publication Critical patent/JP6863897B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017536271A 2015-01-09 2016-01-08 Ｃｘｃｒ４結合分子 Active JP6863897B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015900054A AU2015900054A0 (en) 2015-01-09 CXCR4 binding molecules
AU2015900054 2015-01-09
PCT/AU2016/050005 WO2016109872A1 (en) 2015-01-09 2016-01-08 Cxcr4 binding molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020121974A Division JP7212009B2 (ja) 2015-01-09 2020-07-16 Ｃｘｃｒ４結合分子

Publications (3)

Publication Number Publication Date
JP2018504112A JP2018504112A (ja) 2018-02-15
JP2018504112A5 true JP2018504112A5 (enExample) 2019-11-14
JP6863897B2 JP6863897B2 (ja) 2021-04-21

Family

ID=56355354

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017536271A Active JP6863897B2 (ja) 2015-01-09 2016-01-08 Ｃｘｃｒ４結合分子
JP2020121974A Active JP7212009B2 (ja) 2015-01-09 2020-07-16 Ｃｘｃｒ４結合分子
JP2022181132A Pending JP2023015277A (ja) 2015-01-09 2022-11-11 Ｃｘｃｒ４結合分子

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020121974A Active JP7212009B2 (ja) 2015-01-09 2020-07-16 Ｃｘｃｒ４結合分子
JP2022181132A Pending JP2023015277A (ja) 2015-01-09 2022-11-11 Ｃｘｃｒ４結合分子

Country Status (11)

Country Link
US (2) US10538596B2 (enExample)
EP (2) EP3242685B1 (enExample)
JP (3) JP6863897B2 (enExample)
CN (2) CN114478773A (enExample)
AU (3) AU2016206191B2 (enExample)
DK (1) DK3242685T3 (enExample)
ES (1) ES2924394T3 (enExample)
HR (1) HRP20220860T1 (enExample)
LT (1) LT3242685T (enExample)
SG (2) SG10202111844VA (enExample)
WO (1) WO2016109872A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3242685T3 (da) * 2015-01-09 2022-07-25 Adalta Ltd Cxcr4-bindende molekyler
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3535293A1 (en) 2016-11-07 2019-09-11 Crossbeta Biosciences B.V. Novel amyloid beta oligomer specific binding molecule
WO2018130702A1 (en) * 2017-01-16 2018-07-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Improved multi tyrosine kinase inhibitor therapy
KR20200103018A (ko) * 2017-12-19 2020-09-01 주식회사 지피씨알 Gpcr 헤테로머 억제제 및 이의 용도
CN113661240B (zh) * 2019-04-02 2024-11-05 伊莱利利公司 选择和检测结合肽的方法
KR20210156849A (ko) * 2019-05-17 2021-12-27 주식회사 지피씨알 Gpcr 헤테로머 저해제들 및 이의 용도
JP7365674B2 (ja) * 2019-08-29 2023-10-20 国立大学法人 長崎大学 アスペルギローマモデル非ヒト動物
CN110804100A (zh) * 2019-11-01 2020-02-18 中国人民解放军陆军特色医学中心 融合多肽及其在增强干细胞归巢能力和抗凋亡能力中的应用和药物组合物
EP4118117A1 (en) * 2020-03-13 2023-01-18 Julius-Maximilians-Universität Würzburg Affinity matured and humanized binding domains targeting ror2
WO2023092177A1 (en) * 2021-11-23 2023-06-01 Adalta Limited Rank-l binding molecules
CN114533884A (zh) * 2022-04-20 2022-05-27 澳门大学 一种联合治疗癌症的药物及s100a9-cxcl12信号抑制剂的应用
JP2023172979A (ja) * 2022-05-24 2023-12-07 国立大学法人京都大学 ポリペプチド
EP4740013A1 (en) * 2023-07-07 2026-05-13 AdAlta Limited Linking receptor occupancy to efficacy of cxcr4 antagonists

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US196A (en) 1837-05-15 Machine for mowing and heaping grain
US4439A (en) 1846-04-04 Improvement in cleansing fish-oils
US4475A (en) 1846-04-25 Henry johnson
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US5206154A (en) 1985-01-28 1993-04-27 Xoma Corporation Method of producing cecropins by microbiological techniques
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5215896A (en) 1987-03-20 1993-06-01 Creative Biomolecules, Inc. Leader sequences for the production of recombinant proteins
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
SE8804074D0 (sv) 1988-11-10 1988-11-10 Pharmacia Ab Sensorenhet och dess anvaendning i biosensorsystem
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
WO1994004688A2 (en) 1992-08-21 1994-03-03 The University Of British Columbia Cationic peptides and method for production
US5648244A (en) 1993-09-27 1997-07-15 President And Fellows Of Harvard College Production, purification, cleavage and use of fusion peptides
US5485277A (en) 1994-07-26 1996-01-16 Physical Optics Corporation Surface plasmon resonance sensor and methods for the utilization thereof
US6037145A (en) 1994-09-07 2000-03-14 Suntory Limited Process for production of protein
US5567301A (en) 1995-03-01 1996-10-22 Illinois Institute Of Technology Antibody covalently bound film immunobiosensor
US5972639A (en) 1997-07-24 1999-10-26 Irori Fluorescence-based assays for measuring cell proliferation
DE19818790A1 (de) 1998-04-27 1999-10-28 Affina Immuntechnik Gmbh Immunadsorptionsmatrix, Verfahren zu ihrer Herstellung und ihre Verwendung
ATE370961T1 (de) 1998-05-06 2007-09-15 Genentech Inc Reinigung von antikörpern durch ionenaustauschchromatographie
US6613548B1 (en) 1998-07-31 2003-09-02 Pierce Biotechnology, Inc. Fusion products containing insoluble proteinaceous tag
US6190908B1 (en) 1998-08-12 2001-02-20 The Scripps Research Institute Modulation of polypeptide display on modified filamentous phage
US6306610B1 (en) 1998-09-18 2001-10-23 Massachusetts Institute Of Technology Biological applications of quantum dots
US6242219B1 (en) 1999-03-18 2001-06-05 Xoma (Us) Llc Methods for recombinant peptide production
EP1187928B1 (en) 1999-06-30 2007-05-23 Evotec AG Virus like particles, preparation and use in screening and functional genomics
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20060228364A1 (en) 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
WO2001081614A2 (en) 2000-04-25 2001-11-01 Chemicon International Cell proliferation assay
WO2002026292A1 (de) 2000-09-28 2002-04-04 Affina Immuntechnik Gmbh Durchflussvorrichtung zum trennen von substanzen in körperflüssigkeiten, insbesondere blut und dessen verwendung
ATE457355T1 (de) 2002-05-24 2010-02-15 Medtronic Inc Verfahren und dna-konstrukte zur produktion von polypeptiden mit hoher ausbeute
US8574590B2 (en) 2003-07-30 2013-11-05 Integral Molecular, Inc. Lipoparticles comprising proteins, methods of making, and using the same
US20080299042A1 (en) * 2004-04-30 2008-12-04 Biogen Idec Ma Inc. Membrane Associated Molecules
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
DK1751181T3 (da) * 2004-06-02 2012-11-26 Adalta Pty Ltd BINDINGSDELE, DER ER BASERET PÅ HAJ IgNAR-DOMÆNER
US7807704B2 (en) 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
WO2007115232A2 (en) 2006-03-30 2007-10-11 Chemocentryx, Inc. Cxcr4 modulators
SI2066351T1 (sl) * 2006-10-02 2016-02-29 E.R. Squibb & Sons, L.L.C. Humana protitelesa, ki vežejo cxcr4 in njihova uporaba
US8088895B2 (en) 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
WO2008055314A1 (en) 2006-11-10 2008-05-15 Dimerix Bioscience Pty Ltd Thyrotropin releasing hormone receptor-orexin receptor hetero-dimers/-oligomers
US20080261978A1 (en) 2007-03-08 2008-10-23 Clark Michael P Chemokine receptor modulators
KR20110014141A (ko) 2008-03-20 2011-02-10 카롤러스 테라퓨틱스, 인코포레이티드 염증을 치료하는 방법
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
WO2010033913A1 (en) * 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
KR101701367B1 (ko) 2008-11-04 2017-02-02 케모센트릭스, 인크. Ｃｘｃｒ７의 모듈레이터
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
HUE043001T2 (hu) * 2011-11-09 2019-07-29 Bristol Myers Squibb Co Hematológiai malignómák kezelése anti-CXCR4 antitesttel
AU2014226650A1 (en) * 2013-03-08 2015-10-01 Curonz Holdings Company Limited Neural regeneration peptides and uses therefor
DK3242685T3 (da) * 2015-01-09 2022-07-25 Adalta Ltd Cxcr4-bindende molekyler

Similar Documents

Publication Publication Date Title
AU2024264558B2 (en) Bicyclic peptide ligands specific for Nectin-4
TW496870B (en) Compositions methods for stimulating megakaryocyte growth and differentiation
JP2022105138A5 (enExample)
JP2023505492A5 (enExample)
JP2021522175A5 (enExample)
ES2199941T3 (es) Anticuerpos monoclonales contra el receptor de la interferona, con actividad neutralizadora contra el interferon de tipo j.
JP2019506841A5 (enExample)
HRP20220865T1 (hr) T stanični receptori
JP2019511222A5 (enExample)
HRP20220860T1 (hr) Cxcr4 vezujuće molekule
JP2017079785A5 (enExample)
JP2018522563A5 (enExample)
JP2019513764A5 (enExample)
RU2016101711A (ru) Высокостабильный т-клеточный рецептор и способ его получения и применения
JP2020503262A5 (ja) アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物
JP2021502980A5 (enExample)
JP2017522903A5 (enExample)
BRPI0706788A2 (pt) anticorpos antagonistas il-17
TW200531979A (en) Inhibitors of type 2 vascular endothelial growth factor receptors
JP2015522576A5 (enExample)
ES2926511T3 (es) Anticuerpos anti-CLEVER-1 humanizados y utilización de los mismos
JP2011502479A5 (enExample)
JPWO2019107530A5 (enExample)
JP2023538422A5 (enExample)
JP2006506942A5 (enExample)